Latest 10-K annual reports

Stoneridge, Inc. reported a significant net loss of $102.8 million for fiscal year 2025, alongside a strategic divestiture of its Control Devices segment in January 2026 to focus on high-growth electronics and Brazil markets.

Peoples Financial Services Corp. announced a significant increase in net income for 2025, driven by a full year of FNCB merger operations and reduced credit loss provisions, alongside improved asset quality and capital ratios.

Aprea Therapeutics, a clinical-stage precision oncology company, reported a net loss of $12.6 million for 2025 and warned of substantial doubt about its ability to continue as a going concern, alongside a Nasdaq minimum bid price deficiency.

D. Boral ARC Acquisition I Corp., a SPAC, announced a definitive merger agreement with Exascale Labs Inc. valued at $500 million, while auditors express going concern doubt.

Lifecore Biomedical, Inc. reports significant revenue and cash flow improvements for its transition period, despite ongoing net losses and internal control weaknesses.

Coya Therapeutics, a clinical-stage biotech, reported a $21.2 million net loss for 2025 while advancing its lead asset COYA 302 into Phase 2 for ALS and receiving IND acceptance for FTD, supported by a recent $11.1 million financing.

Nuvera Communications, Inc. reported a significant increase in net income for 2025, driven by growth in governmental support and data services, despite declines in legacy voice and video revenues, as its fiber network build-out progresses.

Zenas BioPharma announced positive Phase 3 results for obexelimab in IgG4-RD and promising Phase 2 RMS data, while reporting significant net losses and a going concern warning from its auditor.

OPAL Fuels Inc. announced a significant increase in total revenues and net income for the fiscal year ended December 31, 2025, driven by robust performance in its RNG Fuel and Fuel Station Services segments, alongside strategic tax credit sales.

WW International has successfully emerged from Chapter 11 bankruptcy, significantly reducing its debt and restructuring its operations to focus on an integrated weight management model.

Olema Pharmaceuticals progresses lead product candidate palazestrant into pivotal Phase 3 trials and initiates Phase 1 for OP-3136, while reporting continued net losses for 2025.

CytomX Therapeutics reports positive early clinical data for Varseta-M and CX-801, alongside a significant net loss and collaboration terminations, while securing capital into Q2 2027.

Contango ORE, Inc. reported a reduced net loss in fiscal 2025, driven by increased distributions from its Manh Choh Project and strategic capital raises, while progressing major exploration and merger initiatives.

Dollar Tree reports a 10.4% net sales increase and 5.3% comparable store sales growth for fiscal 2025, driven by strategic initiatives and multi-price expansion, while managing tariff uncertainties.

Alto Neuroscience's 2025 annual report highlights progress in its precision psychiatry pipeline with new funding, despite a setback in its ALTO-100 MDD trial.

Townsquare Media reports a 5.2% revenue decline in 2025, driven by broadcast advertising, but sees operating income double due to lower impairment charges.

bioAffinity Technologies reported a 34% consolidated revenue decrease to $6.2 million in 2025, driven by strategic divestitures, while its CyPath Lung diagnostic revenue surged 87% and the company raised $16.9 million in equity.

Aspen Aerogels, Inc. reported a significant net loss of $389.6 million in 2025, driven by a 40% revenue decline and a substantial impairment charge related to its Statesboro Plant.

California BanCorp achieved significant net income growth in 2025, driven by a successful merger and strategic derisking efforts, despite a cooling California economy.

Ernexa Therapeutics Inc. reported significant losses and a going concern warning in its 2025 annual report, despite recent capital raises and progress in its preclinical cell therapy programs.

Bayview Acquisition Corp, a blank check company, faces Nasdaq delisting and significant shareholder redemptions while pursuing a merger with Oabay Holding Company.

Cardio Diagnostics Holdings, Inc. reported a reduced net loss in 2025 compared to 2024, despite a decline in revenue, as it continues to focus on commercializing its AI-driven cardiovascular diagnostic tests and expanding market reach.

Annovis Bio reports progress in its pivotal Phase 3 Alzheimer's and Open-Label Extension Parkinson's trials for buntanetap, while acknowledging substantial doubt about its ability to continue as a going concern without additional financing.

Abacus Global Management, Inc. reported a significant financial turnaround in 2025, achieving substantial net income and revenue growth across its key segments, driven by strategic acquisitions and expanded asset management.

Bank of Marin Bancorp reported a net loss of $35.7 million in 2025, driven by strategic balance sheet repositioning and securities sales, while addressing a material weakness in internal controls.

Dune Acquisition Corp. II, a blank check company, reported a net income of $3.35 million for the year ended December 31, 2025, primarily from trust account interest, but faces substantial doubt about its ability to continue as a going concern without a business combination.

InPoint Commercial Real Estate Income, Inc. reported a net loss of $7.6 million for 2025, a significant decline from the prior year, driven by a reduced loan portfolio and real estate losses, while outlining a strategic plan to liquidate real estate owned and redeploy proceeds into first mortgage loans.

CervoMed Inc. reported a significant net loss of $27.0 million for 2025, while advancing its lead drug candidate, neflamapimod, to a planned Phase 3 trial for Dementia with Lewy Bodies, despite ongoing funding needs.

NexMetals Mining Corp. details significant exploration advancements, key financings, and corporate governance updates in its 2025 annual report, while acknowledging ongoing operational losses and future funding needs.

KinderCare Learning Companies, Inc. reported a significantly wider net loss for fiscal year 2025, driven by substantial goodwill impairment and decreased same-center enrollment, despite overall revenue growth.